<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Immunol</journal-id><journal-title>BMC Immunology</journal-title><issn pub-type="epub">1471-2172</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2172-10-24</article-id><article-id pub-id-type="pmid">19409109</article-id><article-id pub-id-type="doi">10.1186/1471-2172-10-24</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Association of IL-10 and IL-10R&#x003b2; gene polymorphisms with graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling donor</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" contrib-type="author"><name><surname>Sivula</surname><given-names>Jyrki</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jyrki.sivula@helsinki.fi</email></contrib><contrib id="A2" equal-contrib="yes" contrib-type="author"><name><surname>Turpeinen</surname><given-names>Hannu</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>hannu.turpeinen@veripalvelu.fi</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Volin</surname><given-names>Liisa</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>liisa.volin@hus.fi</email></contrib><contrib id="A4" corresp="yes" contrib-type="author"><name><surname>Partanen</surname><given-names>Jukka</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jukka.partanen@veripalvelu.fi</email></contrib></contrib-group><aff id="I1"><label>1</label>Research and Development, Finnish Red Cross Blood Service, Helsinki, Finland</aff><aff id="I2"><label>2</label>Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>4</day><month>5</month><year>2009</year></pub-date><volume>10</volume><fpage>24</fpage><lpage>24</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2172/10/24"/><history><date date-type="received"><day>23</day><month>6</month><year>2008</year></date><date date-type="accepted"><day>4</day><month>5</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Sivula et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Sivula et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Sivula Jyrki jyrki.sivula@helsinki.fi </dc:author><dc:title> Association of IL-10 and IL-10R&#x003b2; gene polymorphisms with graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling donor </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>BMC Immunology 10(1): 24-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2172(2009)10:1&#x0003c;24&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2172</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Extensive allelic matching in the human leukocyte antigen (HLA) genes is regarded as a prerequisite for good clinical success of allogeneic haematopoietic stem cell transplantation (HSCT). Also other genetic factors can be assumed to play a role in preventing and controlling the complications associated with allogeneic HSCT, in particular graft-versus-host disease (GvHD). Interleukin-10 (IL-10) and its receptor (IL-10R), key regulators of the immune response, are among these candidates. We studied the association of IL-10 and IL-10R&#x003b2; gene polymorphisms with the occurrence of GvHD in 309 HLA-identical sibling donor and recipient pairs.</p></sec><sec><title>Results</title><p>The difference in genotypic IL-10 production between patient and donor in combination with patient IL-10R&#x003b2; A/A genotype predisposed strongly to acute GvHD (OR = 7.15, p = 0.000023). On the other hand, a combination of same genotypic IL-10 production with patient IL-10R&#x003b2; A/A genotype protected from chronic GvHD (OR = 0.407, p = 0.0097).</p></sec><sec><title>Conclusion</title><p>Our results suggest that IL-10 and IL-10R&#x003b2; genes have a synergistic effect on the risk of GvHD.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Extensive allelic matching in the human leukocyte antigen (HLA) genes between recipient and donor is regarded as a prerequisite for good clinical success of allogeneic haematopoietic stem cell transplantation (HSCT) [<xref ref-type="bibr" rid="B1">1</xref>]. Graft-versus-host disease (GvHD) can not be totally avoided even with fully HLA-matched sibling donors or by using current GvHD prophylaxis, indicating complex and multifactorial nature of GvHD. This has lead into search of novel genetic factors, in addition to the HLA genes, to prevent and predict the occurrence of GvHD. Genes for killer cell immunoglobulin like receptors (KIR), KIR ligands and minor histocompatibility antigens as well as several cytokines and cytokine receptors have obtained a considerable interest [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Cytokine interleukin 10 (IL-10) is a good functional candidate for GvHD-related gene [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. Previous studies have shown that patient or donor IL-10 genotypes separately associate with both acute and chronic GvHD [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. IL-10 is produced by a variety of different cells, of both haematopoietic and non-haematopoietic lineages [<xref ref-type="bibr" rid="B10">10</xref>]. IL-10 is usually regarded as a potent suppressor of the immune responses and hence it is thought to be useful in preventing GvHD. However, it has also been shown to have some immunostimulatory effects [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. Interleukin 10 receptor beta (IL-10R&#x003b2;) is also expressed on several cell types, and its role varies depending on the cell type it is expressed on [<xref ref-type="bibr" rid="B14">14</xref>]. In haematopoietic cell lineages IL-10R&#x003b2; functions as a part of IL-10 receptor together with IL-10 receptor alpha (IL-10R&#x003b1;). IL-10R&#x003b1;, the IL-10 specific part of the receptor complex, is only expressed on haematopoietic cells [<xref ref-type="bibr" rid="B5">5</xref>]. Thus in haematopoietic cells IL-10R&#x003b2; is mediating the IL-10 signal. In many non-haematopoietic cell lineages IL-10R&#x003b2; functions as a part of a receptor for other cytokines [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>To address the role of IL-10 and IL-10R&#x003b2; in HSCT we here report the effects of polymorphisms in these genes on the incidence of acute and chronic GvHD in 309 Finnish HSCT recipients who had an HLA identical sibling donor. In particular, we addressed the questions of interplay of patient- and donor-specific factors of IL-10 and IL-10R&#x003b2; genes.</p></sec><sec><title>Results</title><p>Altogether 309 allogeneic HSCT recipients and their HLA-identical sibling donors were included in the study. The demographic and other background information is given in Table <xref ref-type="table" rid="T1">1</xref>. Genetic variation in IL-10 and IL-10R&#x003b2; genes was studied and genetic association with the occurrence of GvHD in the patients was tested.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Sample demographics</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold><italic>Patient age</italic></bold>, <italic>years mean (range)</italic></td><td align="center">47 (17&#x02013;66)</td></tr><tr><td align="center"><bold><italic>Donor age</italic></bold>, <italic>years mean (range)</italic></td><td align="center">45 (11&#x02013;68)</td></tr></thead><tbody><tr><td align="center"><bold><italic>Diagnosis</italic></bold>, <italic>frequency</italic></td><td></td></tr><tr><td align="center">Acute myeloid leukaemia</td><td align="center">77</td></tr><tr><td align="center">Multiple myeloma</td><td align="center">54</td></tr><tr><td align="center">Acute lymphoid leukaemia</td><td align="center">48</td></tr><tr><td align="center">Chronic lymphoid leukaemia</td><td align="center">45</td></tr><tr><td align="center">Myelodysplastic syndrome</td><td align="center">23</td></tr><tr><td align="center">Chronic myeloid leukaemia</td><td align="center">13</td></tr><tr><td align="center">Non-Hodgkin lymphoma</td><td align="center">13</td></tr><tr><td align="center">Other</td><td align="center">36</td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="center"><bold><italic>Disease status</italic></bold></td><td></td></tr><tr><td align="center">Good prognosis</td><td align="center">148</td></tr><tr><td align="center">Bad prognosis</td><td align="center">142</td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="center"><bold><italic>Gender</italic></bold>, <italic>patient-donor</italic></td><td></td></tr><tr><td align="center">male-male</td><td align="center">82</td></tr><tr><td align="center">male-female</td><td align="center">67</td></tr><tr><td align="center">female-male</td><td align="center">76</td></tr><tr><td align="center">female-female</td><td align="center">63</td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="center"><bold><italic>Graft origin</italic></bold></td><td></td></tr><tr><td align="center">Peripheral blood</td><td align="center">128</td></tr><tr><td align="center">Bone marrow</td><td align="center">162</td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="center"><bold><italic>Conditioning</italic></bold></td><td></td></tr><tr><td align="center">Myeloablative</td><td align="center">233</td></tr><tr><td align="center">Other</td><td align="center">57</td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="center"><bold><italic>GvHD prevention</italic></bold></td><td></td></tr><tr><td align="center">Cyclosporine, Methotrexate and Methylprednisolone</td><td align="center">207</td></tr><tr><td align="center">Cyclosporine and Mycophenolate Mofetil</td><td align="center">46</td></tr><tr><td align="center">Cyclosporine and Methotrexate</td><td align="center">37</td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="center"><bold><italic>Acute GvHD</italic></bold></td><td></td></tr><tr><td align="center">No</td><td align="center">197</td></tr><tr><td align="center">grade III&#x02013;IV</td><td align="center">29</td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="center"><bold><italic>Chronic GvHD</italic></bold></td><td></td></tr><tr><td align="center">No</td><td align="center">117</td></tr><tr><td align="center">Extensive</td><td align="center">72</td></tr></tbody></table></table-wrap><sec><title>1. Genotype and haplotype association of IL-10 and IL-10R&#x003b2; gene polymorphisms with GvHD</title><p>The distributions of genotypes and haplotypes in patients and donors were studied for their association with the occurrence of acute (none versus grade III&#x02013;IV) and chronic (none versus extensive) GvHD (Additional files <xref ref-type="supplementary-material" rid="S1">1</xref> and <xref ref-type="supplementary-material" rid="S2">2</xref>).</p><p>In the patients, the genotype rs1800872 A/A in IL-10 gene predisposed to grade III&#x02013;IV acute GvHD (p = 0.031, OR = 3.83) when compared to other genotypes (A/C and C/C). As a result of strong linkage disequilibrium between the IL-10 gene markers, the same association was also detected for the rs1800872 &#x02013; rs1800896 haplotypes (Additional files <xref ref-type="supplementary-material" rid="S1">1</xref> and <xref ref-type="supplementary-material" rid="S2">2</xref>). In the IL-10R&#x003b2; gene, patient's A/A genotype predisposed to acute GvHD (p = 0.0035, OR = 3.88) and A/G genotype showed protection from it (p = 0.017, OR = 0.30).</p><p>When the patients and donors were stratified based on their IL-10 and IL-10R&#x003b2; genotypes together, this approach did not suggest any novel genetic association.</p><p>In the patients, none of the genotypes of IL-10 or IL-10R&#x003b2; showed statistically significant association with chronic GvHD. In the donors, no genotypes or haplotypes showed statistically significant association with either chronic or acute GvHD (Additional files <xref ref-type="supplementary-material" rid="S1">1</xref> and <xref ref-type="supplementary-material" rid="S2">2</xref>).</p><p>Previously, Lin et al. [<xref ref-type="bibr" rid="B7">7</xref>] described that a certain combination of patient IL-10 and donor IL-10R&#x003b2; polymorphisms protected very strongly from acute GvHD. Hence, we carried out similar analysis (Table <xref ref-type="table" rid="T2">2</xref>). We also found that none of the three sibling pairs in our data set with IL-10 rs1800872 A/A (patient) &#x02013; IL-10R&#x003b2; rs28341676 G/G (donor) genotypes actually resulted in acute GvHD, but no statistical significancy or similar trend of decreasing acute GvHD frequency as Lin et al. observed toward this genotype combination could be seen.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Incidence of grade III&#x02013;IV acute GvHD according to patient IL-10 (-592) rs1800872 and donor IL-10R&#x003b2;(+238) rs28341676 genotypes/all cases (percent)</p></caption><table frame="hsides" rules="groups"><tbody><tr><td></td><td></td><td align="center" colspan="3"><bold>Patient IL-10 rs1800872</bold></td></tr><tr><td></td><td></td><td colspan="3"><hr></hr></td></tr><tr><td></td><td></td><td align="center"><bold>A/A</bold></td><td align="center"><bold>A/C</bold></td><td align="center"><bold>C/C</bold></td></tr><tr><td></td><td colspan="4"><hr></hr></td></tr><tr><td align="center"><bold>Donor IL-10R&#x003b2; rs28341676</bold></td><td align="center"><bold>A/A</bold></td><td align="center">3/8 (38%)</td><td align="center">5/53 (9%)</td><td align="center">9/90 (10%)</td></tr><tr><td></td><td align="center"><bold>A/G</bold></td><td align="center">2/5 (40%)</td><td align="center">4/32 (13%)</td><td align="center">4/70 (6%)</td></tr><tr><td></td><td align="center"><bold>G/G</bold></td><td align="center">0/3 (0%)</td><td align="center">0/12 (0%)</td><td align="center">1/24 (4%)</td></tr></tbody></table></table-wrap></sec><sec><title>2. Associations with predicted IL-10 production levels</title><p>Genotype classes with different predicted production levels were tested for their association with the occurrence of GvHD but no statistically significant results could be found. However, patient intermediate genotypic production level was borderline protective from acute GvHD (p = 0.073, OR = 0.431).</p><p>We furthermore subdivided the study group based on their IL-10R&#x003b2; genotype and whether the donor &#x02013; recipient pair had the same or different production level of IL-10 (Additional file <xref ref-type="supplementary-material" rid="S3">3</xref>). Those patients with the IL-10R&#x003b2; A/A genotype who received the graft from a donor with a different predicted IL-10 level to that of the recipient, had a very high risk for acute GvHD (p = 0.000023, OR = 7.15). Similarly, when the IL-10R&#x003b2; A/A homozygous patients received a graft with a same IL-10 production level, they were protected from chronic GvHD (p = 0.0097, OR = 0.407; Additional file <xref ref-type="supplementary-material" rid="S3">3</xref>).</p></sec><sec><title>3. Multivariate analysis</title><p>Logistic regression multivariate analysis was then performed to test if the statistically significant results observed in univariate analyses would hold, when tested in the context of other known factors influencing GvHD; disease status (good prognosis versus bad prognosis), gender match (male versus female donor), graft origin (bone marrow versus peripheral blood), pre-transplantation conditioning (myeloablative versus other) and aGvHD as a risk factor for cGvHD. All statistically significant results of univariate IL-10 and IL-10R&#x003b2; remained significant in multivariable analyses. Results of these analyses are shown in Table <xref ref-type="table" rid="T3">3</xref>. We also performed multivariable analyses to see if the studied IL-10 and IL-10R&#x003b2; polymorphisms correlated with the other factors used in these analysis. These results showed no correlation between disease status, gender match, graft origin and pre-transplantation conditioning, and the IL-10 and IL-10R&#x003b2; polymorphisms.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Multivariable logistic regression analysis of acute and chronic GvHD</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Acute GvHD</td><td align="center">B</td><td align="center">S.E.</td><td align="center">p</td></tr></thead><tbody><tr><td align="left">Disease status</td><td align="center">0.92</td><td align="center">0.47</td><td align="center">0.053</td></tr><tr><td align="left">Gender match</td><td align="center">-0.29</td><td align="center">0.50</td><td align="center">0.56</td></tr><tr><td align="left">Graft origin</td><td align="center">0.34</td><td align="center">0.50</td><td align="center">0.49</td></tr><tr><td align="left">Conditioning</td><td align="center">0.055</td><td align="center">0.60</td><td align="center">0.93</td></tr><tr><td align="left">Patient IL10 rs1800872 A/A</td><td align="center">1.30</td><td align="center">0.60</td><td align="center">0.031</td></tr><tr><td align="left">Constant</td><td align="center">-2.65</td><td align="center">0.53</td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">Acute GvHD</td><td align="center">B</td><td align="center">S.E.</td><td align="center">p</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">Disease status</td><td align="center">1.26</td><td align="center">0.53</td><td align="center">0.017</td></tr><tr><td align="left">Gender match</td><td align="center">-0.32</td><td align="center">0.50</td><td align="center">0.53</td></tr><tr><td align="left">Graft origin</td><td align="center">0.13</td><td align="center">0.49</td><td align="center">0.80</td></tr><tr><td align="left">Conditioning</td><td align="center">-0.11</td><td align="center">0.61</td><td align="center">0.85</td></tr><tr><td align="left">Patient IL10R&#x003b2; rs28341676 A/A</td><td align="center">1.33</td><td align="center">0.46</td><td align="center">0.0041</td></tr><tr><td align="left">Constant</td><td align="center">-3.13</td><td align="center">0.58</td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">Acute GvHD</td><td align="center">B</td><td align="center">S.E.</td><td align="center">p</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">Disease status</td><td align="center">1.26</td><td align="center">0.53</td><td align="center">0.017</td></tr><tr><td align="left">Gender match</td><td align="center">-0.39</td><td align="center">0.56</td><td align="center">0.49</td></tr><tr><td align="left">Graft origin</td><td align="center">0.09</td><td align="center">0.52</td><td align="center">0.86</td></tr><tr><td align="left">Conditioning</td><td align="center">-0.52</td><td align="center">0.67</td><td align="center">0.44</td></tr><tr><td align="left">IL-10 production level different and patient IL-10R&#x003b2; A/A</td><td align="center">2.16</td><td align="center">0.49</td><td align="center">0.0000088</td></tr><tr><td align="left">Constant</td><td align="center">-3.02</td><td align="center">0.56</td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">Chronic GvHD</td><td align="center">B</td><td align="center">S.E.</td><td align="center">p</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">Disease status</td><td align="center">0.38</td><td align="center">0.50</td><td align="center">0.50</td></tr><tr><td align="left">Gender match</td><td align="center">-1.20</td><td align="center">0.55</td><td align="center">0.028</td></tr><tr><td align="left">Graft origin</td><td align="center">-1.58</td><td align="center">0.48</td><td align="center">0.0010</td></tr><tr><td align="left">Conditioning</td><td align="center">1.10</td><td align="center">0.65</td><td align="center">0.087</td></tr><tr><td align="left">aGvHD</td><td align="center">2.64</td><td align="center">0.95</td><td align="center">0.0052</td></tr><tr><td align="left">IL-10 production level same and patient IL-10R&#x003b2; A/A</td><td align="center">-1.18</td><td align="center">0.50</td><td align="center">0.017</td></tr><tr><td align="left">Constant</td><td align="center">0.58</td><td align="center">0.43</td><td></td></tr></tbody></table></table-wrap></sec></sec><sec><title>Discussion</title><p>In the present study we analysed the role of IL-10 and IL-10R&#x003b2; SNPs on the incidence of acute and chronic GvHD after HSCT between HLA-identical siblings. Previously published studies on interaction of IL-10 and HSCT have found association between IL-10 polymorphism and GvHD outcome [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. In these studies the results predominantly rely on polymorphisms of either recipient or donor. Here we addressed the question also by studying the association of the SNPs with GvHD in biologically more meaningful context; that is analysing simultaneously both donor and patient genotypes.</p><p>In our analysis patient IL-10 rs1800872 genotype A/A was associated with worse acute GvHD outcome (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref> and Table <xref ref-type="table" rid="T3">3</xref>). Similar result was also observed with rs1800896 and rs1800872 genotype combination AA/AA. Also patient IL-10R&#x003b2; rs28341676 genotype affected the risk of developing GvHD. Patient IL-10R&#x003b2; rs28341676 A/A predisposed to and A/G protected from grades III&#x02013;IV acute GvHD. Donor IL-10 rs1800896 and rs1800872 or IL-10R&#x003b2; rs28341676 polymorphisms did not have any clear effect on the GvHD outcome (Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>).</p><p>Because the cells of the graft are mainly haematopoietic cells, the effect of IL-10R&#x003b2; polymorphism on the donor side is restricted to recognition of IL-10. Since most of the patient's original haematopoietic cells are eliminated, the effect of IL-10R&#x003b2; on patient side is largely restricted to the signalling of other cytokines where the IL-10R&#x003b2; also functions as a part of the receptor complex. Cytokines known to date to utilise IL-10R&#x003b2; are IL-10, IL-22, IL-26, IL-28A, IL-28B and IL-29 [<xref ref-type="bibr" rid="B14">14</xref>]. Since donor IL-10R&#x003b2; had no significance on GvHD predisposition, the effects of IL-10R&#x003b2; polymorphism would seem to rely largely on functions of these other cytokines utilizing IL-10R&#x003b2; in their signalling.</p><p>When analysing both the patient and donor IL-10 genotypes the results showed a trend for lower risk of developing GvHD when both had similar IL-10 production levels estimated from genotypes (Additional file <xref ref-type="supplementary-material" rid="S3">3</xref>). Similar results were also seen by Bertinetto et al [<xref ref-type="bibr" rid="B18">18</xref>]. In their study the presence of IL-10 rs180087 G allele in both patient and donor was associated with a trend for lower risk of developing GvHD. The rationale for this is the fact that IL-10 is a strong regulator of immune system and it might be that either higher or lower production level of the protein as compared to original one would not be optimal for the patient's immune system. The effect of patient IL-10R&#x003b2; was also amplified when analyzed together with IL-10 production level. IL-10R&#x003b2; A/A strongly predisposed to acute GvHD when patient and donor IL-10 production level differed, but protected from chronic GvHD when patient and donor had similar IL-10 production level (Additional file <xref ref-type="supplementary-material" rid="S3">3</xref> and Table <xref ref-type="table" rid="T3">3</xref>).</p><p>We were not able to reproduce most of the significant results of Lin et al [<xref ref-type="bibr" rid="B7">7</xref>] with our study material. In our results the donor IL-10R&#x003b2; had no significant effect on the GvHD even in combination with IL-10 polymorphisms. Also, patient IL-10 rs1800872 A/A predisposed to acute GvHD (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref> p = 0.031, OR = 3.83). However, as Lin et al also observed, no acute GvHD cases were present among those three pairs with the combination of patient IL-10 rs1800872 A/A and donor IL-10R&#x003b2; rs28341676 G/G (Table <xref ref-type="table" rid="T2">2</xref>). Compared to our results, in Lin et al study the frequency of IL-10 rs1800872 A allele was higher. This might in part explain the striking difference between our results. The rs1800872 A allele is often associated with lower risk of developing GvHD, but there are also studies which show similar association as we found [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. It is possible that the rs1800872 is not it self affecting to the risk of GvHD, but is in linkage disequilibrium with the actual effector. In different populations this linkage might vary and cause the discrepancy in the results.</p><p>In analyses of IL-10R&#x003b2; rs28341676 the results differed between acute and chronic GvHD. Patient IL-10R&#x003b2; A/A predisposed to acute GvHD and seemed to protect from chronic GvHD. The different effect of IL-10R&#x003b2; polymorphism between acute GvHD and chronic GvHD and overall weaker results in chronic GvHD can be understood by the immunologic differences between acute and chronic GvHD. During the period of which acute GvHD is observed, the immune system is just starting to reconstitute anew after the HSCT. Also, many of the effector cells had been developed within the donor. In many cell lineages their numbers start rising only well after the usual 100 days time limit of acute GvHD diagnosis. More cells of donor origin are developing within the recipient during chronic GvHD. The immune system is more mature and complex than in the newly transplanted patient [<xref ref-type="bibr" rid="B19">19</xref>]. Notably, amounts of regulatory cells rise only relatively late in immune reconstitution [<xref ref-type="bibr" rid="B20">20</xref>]. The full reconstitution of immune system after transplantation may take years. Hence it is not surprising that IL-10 and IL-10R&#x003b2; polymorphisms have less effect in chronic GvHD than in acute GvHD. This could also explain the opposing effect of IL-10R&#x003b2; polymorphism in acute GvHD and chronic GvHD.</p><p>We are fully aware of the possible problems in analyzing all the transplantations as a single group. Grafting peripheral blood stem cells instead of bone marrow cells predisposes to higher incidence of chronic GvHD. Also pre-treatment conditioning, fully myeloablative versus reduced intensity conditioning, highly affects the complications after HSCT. To address this issue we performed logistic regression multivariate analysis to test the results of univariate analyses in the context of known GvHD affecting factors; disease status, gender match, graft origin, pre-transplantation conditioning and aGvHD as a risk factor for cGvHD. All the statistically significant results from univariate analyses remained significant in the multivariate analyses (Table <xref ref-type="table" rid="T3">3</xref>). The p-values in this study were not corrected for multiple comparisons. These results need to be validated in other cohorts and further studies are also needed to clarify the relationships between IL-10 and IL-10R&#x003b2;.</p></sec><sec><title>Conclusion</title><p>We didobserve synergistic effect between IL-10 and IL-10R&#x003b2; in predisposition to GvHD. The effect of IL-10R&#x003b2; polymorphism was strengthened when it was analysed together with IL-10 polymorphisms. In our samples similarity of IL-10 production level was associated with lower incidence of both acute and chronic GvHD. Different effect of IL-10R&#x003b2; genotype in acute GvHD and chronic GvHD could be explained by the developing immune system, arise of new regulatory cells and passing cytokine storm associated with the transplantation.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients</title><p>Altogether 309 adult allogeneic HSCT recipients and their HLA-identical sibling donors were included in this retrospective study. All transplantations were performed in a single centre (Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland) between years 1993 and 2005. Clinical data were collected on diagnosis, age, gender match, transplantation protocol, date of transplantation and acute GvHD and chronic GvHD manifestation. GvHD was diagnosed and graded according to standard criteria [<xref ref-type="bibr" rid="B21">21</xref>]. Patient and donor descriptive demographics are shown in Table <xref ref-type="table" rid="T1">1</xref>.</p><p>This study was approved by the Ethical Review Board of the Helsinki University Hospital, Helsinki, Finland.</p></sec><sec><title>IL-10 and IL-10R&#x003b2; genotyping</title><p>Two single nucleotide polymorphisms (SNPs) in IL-10 and one in IL-10R&#x003b2; were genotyped. The IL-10 SNPs at locations -1082 (rs1800896) and -592 (rs1800872) and the IL-10R&#x003b2; SNP at location +238 (rs28341676) were typed using restriction fragment length polymorphism method as described earlier [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. EcoNI recognition site primers and restriction enzyme was used for IL-10.</p><p>In the Finnish population, the selected two markers for IL-10 tag completely the often used three-marker haplotype (-1082 A/G (rs1800896), -819 T/C (rs1800871), and -592 A/C (rs1800872)) for the gene [<xref ref-type="bibr" rid="B23">23</xref>].</p></sec><sec><title>Statistical analysis</title><p>To analyse the effect of IL-10 and IL-10R&#x003b2; polymorphisms on the GvHD outcome we used different combinations of patient and donor genotyping data. We (i) analysed IL-10 and IL-10R&#x003b2; genotypes and haplotypes separately in patients and donors, and (ii) combined the genotyping data from each patient-donor pair. We also (iii) grouped the IL-10 genotypes into three production level groups: high, intermediate and low producing. These groups are based on the effect of IL-10 polymorphisms on the level of protein production as published earlier [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]: IL-10 rs1800896 (SNP1) and rs1800872 (SNP2) genotype combination (SNP1SNP2/SNP1SNP2) GC/GC belongs to high producing, GC/AC and GC/AA to intermediate producing, and AC/AC, AC/AA and AA/AA to low producing group.</p><p>Analyses of different IL-10 and IL-10R&#x003b2; combinations were done in relation to the acute GvHD and chronic GvHD incidence using &#x003c7;<sup>2 </sup>or Fisher's exact tests. Recipients with acute GvHD of grade III&#x02013;IV and their donors formed the positive group which was compared to patients with no acute GvHD and their donors. Chronic GvHD positive group patients had extensive chronic GvHD and their controls had no chronic GvHD. To test the statistically significant results of univariate analyses in the context of other risk factors we constructed a multivariable logistic regression model adjusted for disease status, gender match, graft origin and pre-transplantation conditioning. We also included aGvHD as a risk factor for cGvHD. The SPSS for Windows v15.0 software (SPSS Inc., Chicago, IL, USA) was used for the analyses. All p-values are considered as two-sided and uncorrected for multiple testing. P-values under 0.05 were regarded to indicate statistical significance.</p></sec></sec><sec><title>Abbreviations</title><p>GvHD: Graft versus host disease; aGvHD: Acute graft versus host disease; cGvHD: Chronic graft versus host disease; HLA: Human leukocyte antigen; HSCT: Haematopoietic stem cell transplantation; IL-10: Interleukin-10; IL-10R: Interleukin-10 receptor; IL-10R&#x003b2;: Interleukin-10 receptor beta subunit; IL-10R&#x003b1;: Interleukin-10 receptor alpha subunit; KIR: Killer cell immunoglobulin like receptor.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>LV clinical expertise, JS and HT genetic typing and data analysis. All authors contributed in the study hypothesis and study design and all authors contributed to the preparation of the manuscript. All authors read and approved the final manuscript. JS and HT share an equal contribution to the article.</p></sec><sec><title>Authors' information</title><p>JS, HT and JP: Research and Development, Finnish Red Cross Blood Service, Helsinki, Finland</p><p>LV: Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland</p><p>Address for correspondence: Dr Jukka Partanen, Research and Development, Finnish Red Cross Blood Service, Kivihaantie 7, 00310 Helsinki, Finland. <email>jukka.partanen@bts.redcross.fi</email></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Table s1</bold>. Distribution of IL-10 (-1082) rs1800896 and (-592) rs1800872, and IL-10R&#x003b2; (+238) rs28341676 genotypes and their association with the occurrence of acute and chronic GvHD in the patients</p></caption><media xlink:href="1471-2172-10-24-S1.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p><bold>Table s2</bold>. Distribution of IL-10 (-1082) rs1800896 and (-592) rs1800872, and IL-10R&#x003b2; (+238) rs28341676 genotypes and their association with the occurrence of acute and chronic GvHD in the patients donors</p></caption><media xlink:href="1471-2172-10-24-S2.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S3"><caption><title>Additional file 3</title><p><bold>Table s3</bold>. Incidence of GvHD according to patient IL-10R&#x003b2; (+238) rs28341676 and patient and donor IL-10 genotypic production levels</p></caption><media xlink:href="1471-2172-10-24-S3.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>This research was supported by grants from the Sigrid Juselius Foundation, the Academy of Finland and Government EVO Fund. We would like to thank Sisko Lehmonen and the staff of Tissue Typing Laboratory of the Finnish Red Cross Blood Service for skilful technical help.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petersdorf</surname><given-names>EW</given-names></name></person-group><article-title>HLA matching in allogeneic stem cell transplantation</article-title><source>Current Opinion in Hematology</source><year>2004</year><volume>11</volume><fpage>386</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">15548992</pub-id><pub-id pub-id-type="doi">10.1097/01.moh.0000143701.88042.d9</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Velardi</surname><given-names>A</given-names></name><name><surname>Ruggeri</surname><given-names>L</given-names></name><name><surname>Capanni</surname><given-names>M</given-names></name><name><surname>Mancusi</surname><given-names>A</given-names></name><name><surname>Perruccio</surname><given-names>K</given-names></name><name><surname>Aversa</surname><given-names>F</given-names></name><name><surname>Martelli</surname><given-names>MF</given-names></name></person-group><article-title>Immunotherapy with alloreactive natural killer cells in haploidentical haematopoietic transplantation</article-title><source>Hematol J</source><year>2004</year><volume>5</volume><fpage>S87</fpage><lpage>S90</lpage><pub-id pub-id-type="pmid">15190285</pub-id><pub-id pub-id-type="doi">10.1038/sj.thj.6200429</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dickinson</surname><given-names>AM</given-names></name><name><surname>Middleton</surname><given-names>PG</given-names></name><name><surname>Rocha</surname><given-names>V</given-names></name><name><surname>Gluckman</surname><given-names>E</given-names></name><name><surname>Holler</surname><given-names>E</given-names></name></person-group><article-title>Genetic polymorphisms predicting the outcome of bone marrow transplants</article-title><source>Br J Haematol</source><year>2004</year><volume>127</volume><fpage>479</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">15566351</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2141.2004.05216.x</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonnet</surname><given-names>D</given-names></name><name><surname>Warren</surname><given-names>EH</given-names></name><name><surname>Greenberg</surname><given-names>PD</given-names></name><name><surname>Dick</surname><given-names>JE</given-names></name><name><surname>Riddell</surname><given-names>SR</given-names></name></person-group><article-title>CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells</article-title><source>Proc Natl Acad Sci USA</source><year>1999</year><volume>96</volume><fpage>8639</fpage><lpage>8644</lpage><pub-id pub-id-type="pmid">10411928</pub-id><pub-id pub-id-type="doi">10.1073/pnas.96.15.8639</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>KW</given-names></name><name><surname>de Waal</surname><given-names>MR</given-names></name><name><surname>Coffman</surname><given-names>RL</given-names></name><name><surname>O'Garra</surname><given-names>A</given-names></name></person-group><article-title>Interleukin-10 and the interleukin-10 receptor</article-title><source>Annu Rev Immunol</source><year>2001</year><volume>19</volume><fpage>683</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">11244051</pub-id><pub-id pub-id-type="doi">10.1146/annurev.immunol.19.1.683</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Lee</surname><given-names>NY</given-names></name><name><surname>Sohn</surname><given-names>SK</given-names></name><name><surname>Baek</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>JG</given-names></name><name><surname>Suh</surname><given-names>JS</given-names></name><name><surname>Lee</surname><given-names>KB</given-names></name><name><surname>Shin</surname><given-names>IH</given-names></name></person-group><article-title>IL-10 promoter gene polymorphism associated with the occurrence of chronic GVHD and its clinical course during systemic immunosuppressive treatment for chronic GVHD after allogeneic peripheral blood stem cell transplantation</article-title><source>Transplantation</source><year>2005</year><volume>79</volume><fpage>1615</fpage><lpage>1622</lpage><pub-id pub-id-type="pmid">15940053</pub-id><pub-id pub-id-type="doi">10.1097/01.TP.0000159792.04757.D4</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>MT</given-names></name><name><surname>Storer</surname><given-names>B</given-names></name><name><surname>Martin</surname><given-names>PJ</given-names></name><name><surname>Tseng</surname><given-names>LH</given-names></name><name><surname>Grogan</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>PJ</given-names></name><name><surname>Zhao</surname><given-names>LP</given-names></name><name><surname>Hansen</surname><given-names>JA</given-names></name></person-group><article-title>Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor</article-title><source>Blood</source><year>2005</year><volume>106</volume><fpage>3995</fpage><lpage>4001</lpage><pub-id pub-id-type="pmid">16109775</pub-id><pub-id pub-id-type="doi">10.1182/blood-2004-11-4338</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karabon</surname><given-names>L</given-names></name><name><surname>Wysoczanska</surname><given-names>B</given-names></name><name><surname>Bogunia-Kubik</surname><given-names>K</given-names></name><name><surname>Suchnicki</surname><given-names>K</given-names></name><name><surname>Lange</surname><given-names>A</given-names></name></person-group><article-title>IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft-versus-host disease</article-title><source>Human Immunology</source><year>2005</year><volume>66</volume><fpage>700</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">15993715</pub-id><pub-id pub-id-type="doi">10.1016/j.humimm.2005.02.003</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cavet</surname><given-names>J</given-names></name><name><surname>Middleton</surname><given-names>PG</given-names></name><name><surname>Segall</surname><given-names>M</given-names></name><name><surname>Noreen</surname><given-names>H</given-names></name><name><surname>Davies</surname><given-names>SM</given-names></name><name><surname>Dickinson</surname><given-names>AM</given-names></name></person-group><article-title>Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants</article-title><source>Blood</source><year>1999</year><volume>94</volume><fpage>3941</fpage><lpage>3946</lpage><pub-id pub-id-type="pmid">10572111</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akdis</surname><given-names>CA</given-names></name><name><surname>Blaser</surname><given-names>K</given-names></name></person-group><article-title>Mechanisms of interleukin-10-mediated immune suppression</article-title><source>Immunology</source><year>2001</year><volume>103</volume><fpage>131</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">11412299</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2567.2001.01235.x</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nolan</surname><given-names>KF</given-names></name><name><surname>Strong</surname><given-names>V</given-names></name><name><surname>Soler</surname><given-names>D</given-names></name><name><surname>Fairchild</surname><given-names>PJ</given-names></name><name><surname>Cobbold</surname><given-names>SP</given-names></name><name><surname>Croxton</surname><given-names>R</given-names></name><name><surname>Gonzalo</surname><given-names>JA</given-names></name><name><surname>Rubio</surname><given-names>A</given-names></name><name><surname>Wells</surname><given-names>M</given-names></name><name><surname>Waldmann</surname><given-names>H</given-names></name></person-group><article-title>IL-10-conditioned dendritic cells, decommissioned for recruitment of adaptive immunity, elicit innate inflammatory gene products in response to danger signals</article-title><source>J Immunol</source><year>2004</year><volume>172</volume><fpage>2201</fpage><lpage>2209</lpage><pub-id pub-id-type="pmid">14764687</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>KW</given-names></name><name><surname>O'Garra</surname><given-names>A</given-names></name><name><surname>de Waal</surname><given-names>MR</given-names></name><name><surname>Vieira</surname><given-names>P</given-names></name><name><surname>Mosmann</surname><given-names>TR</given-names></name></person-group><article-title>Interleukin-10</article-title><source>Annu Rev Immunol</source><year>1993</year><volume>11</volume><fpage>165</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">8386517</pub-id><pub-id pub-id-type="doi">10.1146/annurev.iy.11.040193.001121</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reitamo</surname><given-names>S</given-names></name><name><surname>Remitz</surname><given-names>A</given-names></name><name><surname>Tamai</surname><given-names>K</given-names></name><name><surname>Uitto</surname><given-names>J</given-names></name></person-group><article-title>Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts</article-title><source>J Clin Invest</source><year>1994</year><volume>94</volume><fpage>2489</fpage><lpage>2492</lpage><pub-id pub-id-type="pmid">7989607</pub-id><pub-id pub-id-type="doi">10.1172/JCI117618</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donnelly</surname><given-names>RP</given-names></name><name><surname>Sheikh</surname><given-names>F</given-names></name><name><surname>Kotenko</surname><given-names>SV</given-names></name><name><surname>Dickensheets</surname><given-names>H</given-names></name></person-group><article-title>The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain</article-title><source>J Leukoc Biol</source><year>2004</year><volume>76</volume><fpage>314</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">15123776</pub-id><pub-id pub-id-type="doi">10.1189/jlb.0204117</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Socie</surname><given-names>G</given-names></name><name><surname>Loiseau</surname><given-names>P</given-names></name><name><surname>Tamouza</surname><given-names>R</given-names></name><name><surname>Janin</surname><given-names>A</given-names></name><name><surname>Busson</surname><given-names>M</given-names></name><name><surname>Gluckman</surname><given-names>E</given-names></name><name><surname>Charron</surname><given-names>D</given-names></name></person-group><article-title>Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation</article-title><source>Transplantation</source><year>2001</year><volume>72</volume><fpage>699</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">11544434</pub-id><pub-id pub-id-type="doi">10.1097/00007890-200108270-00024</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>MT</given-names></name><name><surname>Storer</surname><given-names>B</given-names></name><name><surname>Martin</surname><given-names>PJ</given-names></name><name><surname>Tseng</surname><given-names>LH</given-names></name><name><surname>Gooley</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>PJ</given-names></name><name><surname>Hansen</surname><given-names>JA</given-names></name></person-group><article-title>Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic cell transplantation</article-title><source>New England Journal of Medicine</source><year>2003</year><volume>349</volume><fpage>2201</fpage><lpage>2210</lpage><pub-id pub-id-type="pmid">14657427</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa022060</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cavet</surname><given-names>J</given-names></name><name><surname>Dickinson</surname><given-names>AM</given-names></name><name><surname>Norden</surname><given-names>J</given-names></name><name><surname>Taylor</surname><given-names>PRA</given-names></name><name><surname>Jackson</surname><given-names>GH</given-names></name><name><surname>Middleton</surname><given-names>PG</given-names></name></person-group><article-title>Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation</article-title><source>Blood</source><year>2001</year><volume>98</volume><fpage>1594</fpage><lpage>1600</lpage><pub-id pub-id-type="pmid">11520812</pub-id><pub-id pub-id-type="doi">10.1182/blood.V98.5.1594</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertinetto</surname><given-names>FE</given-names></name><name><surname>Dall'Omo</surname><given-names>AM</given-names></name><name><surname>Mazzola</surname><given-names>GA</given-names></name><name><surname>Rendine</surname><given-names>S</given-names></name><name><surname>Berrino</surname><given-names>M</given-names></name><name><surname>Bertola</surname><given-names>L</given-names></name><name><surname>Magistroni</surname><given-names>P</given-names></name><name><surname>Caropreso</surname><given-names>P</given-names></name><name><surname>Falda</surname><given-names>M</given-names></name><name><surname>Locatelli</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Role of non-HLA genetic polymorphisms in graft-versus-host disease after haematopoietic stem cell transplantation</article-title><source>International Journal of Immunogenetics</source><year>2006</year><volume>33</volume><fpage>375</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">16984283</pub-id><pub-id pub-id-type="doi">10.1111/j.1744-313X.2006.00630.x</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Storek</surname><given-names>J</given-names></name><name><surname>Dawson</surname><given-names>MA</given-names></name><name><surname>Storer</surname><given-names>B</given-names></name><name><surname>Stevens-Ayers</surname><given-names>T</given-names></name><name><surname>Maloney</surname><given-names>DG</given-names></name><name><surname>Marr</surname><given-names>KA</given-names></name><name><surname>Witherspoon</surname><given-names>RP</given-names></name><name><surname>Bensinger</surname><given-names>W</given-names></name><name><surname>Flowers</surname><given-names>ME</given-names></name><name><surname>Martin</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation</article-title><source>Blood</source><year>2001</year><volume>97</volume><fpage>3380</fpage><lpage>3389</lpage><pub-id pub-id-type="pmid">11369627</pub-id><pub-id pub-id-type="doi">10.1182/blood.V97.11.3380</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olkinuora</surname><given-names>H</given-names></name><name><surname>Talvensaari</surname><given-names>K</given-names></name><name><surname>Kaartinen</surname><given-names>T</given-names></name><name><surname>Siitonen</surname><given-names>S</given-names></name><name><surname>Saarinen-Pihkala</surname><given-names>U</given-names></name><name><surname>Partanen</surname><given-names>J</given-names></name><name><surname>Vettenranta</surname><given-names>K</given-names></name></person-group><article-title>T cell regeneration in pediatric allogeneic stem cell transplantation</article-title><source>Bone Marrow Transplant</source><year>2007</year><volume>39</volume><fpage>149</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">17211435</pub-id><pub-id pub-id-type="doi">10.1038/sj.bmt.1705557</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Przepiorka</surname><given-names>D</given-names></name><name><surname>Weisdorf</surname><given-names>D</given-names></name><name><surname>Martin</surname><given-names>P</given-names></name><name><surname>Klingemann</surname><given-names>HG</given-names></name><name><surname>Beatty</surname><given-names>P</given-names></name><name><surname>Hows</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>ED</given-names></name></person-group><article-title>1994 Consensus Conference on Acute GVHD Grading</article-title><source>Bone Marrow Transplant</source><year>1995</year><volume>15</volume><fpage>825</fpage><lpage>828</lpage><pub-id pub-id-type="pmid">7581076</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>LH</given-names></name><name><surname>Chen</surname><given-names>PJ</given-names></name><name><surname>Lin</surname><given-names>MT</given-names></name><name><surname>Singleton</surname><given-names>K</given-names></name><name><surname>Martin</surname><given-names>EG</given-names></name><name><surname>Yen</surname><given-names>AH</given-names></name><name><surname>Chuang</surname><given-names>SM</given-names></name><name><surname>Martin</surname><given-names>PJ</given-names></name><name><surname>Hansen</surname><given-names>JA</given-names></name></person-group><article-title>Simultaneous genotyping of single nucleotide polymorphisms in the IL-6, IL-10, TNFalpha and TNFbeta genes</article-title><source>Tissue Antigens</source><year>2002</year><volume>59</volume><fpage>280</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">12135426</pub-id><pub-id pub-id-type="doi">10.1034/j.1399-0039.2002.590405.x</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woolley</surname><given-names>N</given-names></name><name><surname>Mustalahti</surname><given-names>K</given-names></name><name><surname>Maki</surname><given-names>M</given-names></name><name><surname>Partanen</surname><given-names>J</given-names></name></person-group><article-title>Cytokine gene polymorphisms and genetic association with coeliac disease in the Finnish population</article-title><source>Scandinavian Journal of Immunology</source><year>2005</year><volume>61</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">15644122</pub-id><pub-id pub-id-type="doi">10.1111/j.0300-9475.2005.01525.x</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suarez</surname><given-names>A</given-names></name><name><surname>Castro</surname><given-names>P</given-names></name><name><surname>Alonso</surname><given-names>R</given-names></name><name><surname>Mozo</surname><given-names>L</given-names></name><name><surname>Gutierrez</surname><given-names>C</given-names></name></person-group><article-title>Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms</article-title><source>Transplantation</source><year>2003</year><volume>75</volume><fpage>711</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">12640314</pub-id><pub-id pub-id-type="doi">10.1097/01.TP.0000055216.19866.9A</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crawley</surname><given-names>E</given-names></name><name><surname>Kay</surname><given-names>R</given-names></name><name><surname>Sillibourne</surname><given-names>J</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Hutchinson</surname><given-names>I</given-names></name><name><surname>Woo</surname><given-names>P</given-names></name></person-group><article-title>Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>1999</year><volume>42</volume><fpage>1101</fpage><lpage>1108</lpage><pub-id pub-id-type="pmid">10366102</pub-id><pub-id pub-id-type="doi">10.1002/1529-0131(199906)42:6&#x0003c;1101::AID-ANR6&#x0003e;3.0.CO;2-Y</pub-id></citation></ref></ref-list></back></article> 